Core Insights - Pharvaris is set to present pivotal Phase 3 data from the RAPIDe-3 study of deucrictibant for on-demand treatment of hereditary angioedema (HAE) attacks at the AAAAI 2026 Annual Meeting [1][2] - The company will also share final data from the Phase 2 CHAPTER-1 study and pharmacokinetic data of the extended-release formulation of deucrictibant [2] Presentation Details - Six abstracts have been accepted for poster presentation, with three featured during a special session [1] - Key presentations include: - A novel kinin biomarker assay for bradykinin-mediated angioedema [2] - Content validity of the Angioedema symptom rating scale (AMRA) [2] - Long-term prophylactic treatment results from the Phase 2 CHAPTER-1 study [2] - Results from the Phase 3 RAPIDe-3 study on oral deucrictibant for HAE attacks [2] - Long-term safety and efficacy results from the Phase 2 CHAPTER-1 study [2] - Sustained therapeutic exposure with the once-daily oral deucrictibant extended-release tablet [2] Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases [4] - The company aims to provide therapies with injectable-like efficacy and the convenience of oral administration [4] - Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsules and is conducting a pivotal Phase 3 study for the extended-release tablet [4]